AUTHOR=Feng Du , Jiang Huixin , Chen Gengjia , Guan Wenhui , Yi Lin , Zhu Yue , Li Yijia , Huang Gengda , He Bin , Tang Junlong , Tang Yujie , Zeng Jiyuan , Zhou Wensheng , Shi Jiayu , Xie Zhanhong , Liu Ming , Xie Xiaohong , Lin Xinqing , Zhou Chengzhi 

TITLE=Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration

JOURNAL=Frontiers in Immunology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1485358

DOI=10.3389/fimmu.2024.1485358

ISSN=1664-3224

ABSTRACT=The STK11 gene mutation is a common genetic alteration in non-small cell lung cancer (NSCLC) and is significantly associated with poor responses to current immunotherapy regimens. Despite its prevalence, there is currently no established standard for front-line treatment in this subtype of NSCLC, underscoring the increasing need for personalized therapeutic strategies. In this report, we present a case of a patient with STK11-mutant NSCLC who was treated with first-line cadonilimab (10mg/kg) in combination with pemetrexed (500mg/m^2) plus carboplatin (AUC=5), resulting in a notable extension of progression-free survival (PFS). This case highlights the potential efficacy and feasibility of combining immunotherapy with chemotherapy in patients with STK11-mutant NSCLC. Additionally, we provide a review of recent advancements in research related to STK11 mutations in lung cancer as reported in the literature.